MigraineMind research summary
Antithrombotic treatment for migraine in patients with patent foramen ovale: multicentre, randomised, active controlled, open label trial.
BMJ | 2026
Clinical trialSummary
This study looked at how well antithrombotic treatment helps prevent migraines. It involved 1,000 adults aged 18 to 64 with patent foramen ovale (PFO). These participants had migraines for over a year and experienced at least four migraine days monthly. The trial took place across 39 hospitals in China. Participants underwent a 12-week screening to confirm eligibility and record headache data. Those with certain medical conditions were excluded from the study. Of the participants, 984 were included in the analysis, with a majority being female. The researchers aimed to assess both the effectiveness and safety of the treatment. They used a randomised, controlled design to ensure reliable results. The findings could help improve migraine management in patients with PFO, potentially leading to better treatment options in the future. Clinical relevance: This research indicates that antithrombotic treatment may effectively reduce migraine frequency in patients with patent foramen ovale.
Key Learning Points
- Antithrombotic treatment may help reduce the frequency of migraines in patients with patent foramen ovale.
- The study involved 1,000 adults aged 18 to 64 who had chronic migraines.
- Participants experienced at least four migraine days each month for over a year before the study.
- The research was conducted across 39 hospitals in China, ensuring a diverse participant group.
- Findings from this study could lead to improved treatment options for migraine management in patients with PFO.
Research Informatics
RANDOMISED CONTROLLED TRIAL
Rivaroxaban showed superior efficacy over metoprolol without major bleeding.
safetyNo major bleeding events occurred.
follow Up12 weeks
conditionMigraine with patent foramen ovale
populationAdults with migraine and PFO, 18-64 years
sample Size1000
primary Outcome≥50% reduction in monthly migraine days or attacks
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.